Valuation: Cipla Limited

Market Cap 1,171B 12.25B 10.58B 9.94B 9.04B 17B 17.28B 116B 45.55B 587B 45.99B 44.99B 1,949B P/E 2027 *
28.2x
P/E 2028 * 22.8x
Enterprise Value 1,065B 11.14B 9.62B 9.04B 8.22B 15.46B 15.72B 106B 41.42B 533B 41.83B 40.92B 1,773B EV / Sales 2027 *
3.44x
EV / Sales 2028 * 2.99x
Free-Float
68.87%
Yield 2027 *
0.9%
Yield 2028 * 1.02%
1 day-0.65%
1 week-1.94%
Current month-1.30%
1 month+2.01%
3 months+9.35%
6 months+3.40%
Current year-9.52%
1 week 15.2
Extreme 15.2
15.3
1 month 14.4
Extreme 14.4
15.5
Current year 12.8
Extreme 12.8
17
1 year 12.8
Extreme 12.8
18.9
3 years 12.8
Extreme 12.8
20
5 years 10.4
Extreme 10.4
20
10 years 4.94
Extreme 4.94
20
Manager TitleAgeSince
Chief Executive Officer - 01/04/2026
President - 18/05/2026
Director of Finance/CFO - 24/07/2026
Director TitleAgeSince
Chairman 90 21/07/1972
Director/Board Member 72 25/07/2014
Director/Board Member 71 30/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.65%-1.94% - - 12.35B
-0.10%-1.08%+17.70%+70.44% 48.57B
-3.26%-1.15%+50.36%+115.32% 40.99B
-0.60%-1.83%-7.11%+15.98% 12.35B
-2.75%+2.45%+14.83%+74.39% 12.2B
-0.19%-0.19%+29.10%+135.91% 9.08B
+1.56%+7.62%+23.93%+39.78% 7.41B
+0.52%+3.93%+39.82%-13.06% 7.13B
-0.07%+2.13%+14.25%+189.31% 6.86B
-2.51%+3.10%-27.59%+27.09% 5.92B
Average -0.80%+1.50%+17.25%+72.80% 16.72B
Weighted average by Cap. -1.16%+1.03%+24.43%+80.72%

Financials

2027 *2028 *
Net sales 310B 3.24B 2.8B 2.63B 2.39B 4.5B 4.57B 30.82B 12.05B 155B 12.17B 11.9B 516B 347B 3.63B 3.14B 2.95B 2.68B 5.04B 5.12B 34.54B 13.5B 174B 13.64B 13.34B 578B
Net income 41.35B 432M 373M 351M 319M 600M 610M 4.11B 1.61B 20.71B 1.62B 1.59B 68.81B 51.42B 538M 464M 436M 397M 746M 759M 5.11B 2B 25.75B 2.02B 1.98B 85.57B
Net Debt -106B -1.11B -958M -900M -819M -1.54B -1.56B -10.55B -4.12B -53.12B -4.16B -4.07B -177B -131B -1.37B -1.19B -1.12B -1.01B -1.91B -1.94B -13.07B -5.11B -65.82B -5.16B -5.05B -219B
Logo Cipla Limited
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Employees
31,369
Date Price Change
14/08/26 USD 15.20 -0.65%
13/08/26 USD 15.30 0.00%
12/08/26 USD 15.30 0.00%
11/08/26 USD 15.30 0.00%
10/08/26 USD 15.30 -1.29%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1,450.00INR
Average target price
1,509.08INR
Spread / Average Target
+4.07%

Quarterly revenue - Rate of surprise